Nuvation Bio Inc.NUVB stock score: 40/100

$3.81 · +0.79% · Scored Nov 19, 2026

Technical
30
Fundamental
42
News
56

The reading

Nuvation Bio (NUVB) scores 40 out of 100, which reads weak, higher than 23% of Healthcare stocks and 22% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 42, technicals 30.

Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.

On the daily chart, trend-following indicators average 13 and contrarian oscillators 70 — a split worth reading before trusting the technical total.

News sentiment is neutral at 56; it is shown, not counted in the composite.

Since Aug 22, 2026 the composite has ranged from 36 to 55, and it is down 13 points over the period.

About Nuvation Bio

Nuvation Bio (NUVB) is a commercial-stage biopharmaceutical company that develops and sells targeted cancer therapies. Its marketed drug, IBTROZI, is a pill for adults with advanced non-small cell lung cancer driven by ROS1 gene fusions, and it gained the drug through its acquisition of AnHeart Therapeutics. Nuvation sells IBTROZI directly in the United States, while partners handle the drug in other markets, including China, Japan and Europe. Its main pipeline candidate, safusidenib, is an IDH1 inhibitor in late-stage testing for IDH1-mutant glioma, a type of brain tumor, and the company also has earlier programs, including a drug-drug conjugate. Nuvation earns revenue from IBTROZI product sales in the United States and from royalties, milestones and supply payments from regional partners, and it has funded development with cash on hand and financing.

In ROS1-positive lung cancer, Nuvation competes with Bristol Myers Squibb, Pfizer and Roche, which sell other ROS1-targeted drugs, while in IDH-mutant glioma it would compete with Servier’s Voranigo. Its edge rests on clinical data showing durable responses, including in patients whose cancer has spread to the brain, and on a focused commercial team aimed at a small group of oncologists. Investors who follow NUVB stock tend to watch IBTROZI sales and new patient starts. Approvals and launches by partners outside the United States are closely followed. Progress of the safusidenib late-stage trial, operating expenses and cash runway are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward NUVB’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

42

Pulling it up

  • Quick ratio measures a company's ability to meet short-term obligations with liquid assets.

  • Price target score compares the current stock price to analyst consensus targets.

  • Current assets divided by current liabilities: the ability to pay short-term bills.

Holding it back

  • Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.

  • Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.

  • 5-year earnings growth evaluates long-term profit trajectory and consistency.

37 weighted scorers; 2 had no data today and are left out rather than counted as zero.

Technical · daily

21

Pulling it up

  • Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.

  • Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.

  • Bollinger Bands (20-period) plot standard deviations above and below a moving average.

Holding it back

  • S&P 500 52-week comparison evaluates the stock's annual performance relative to the broader market.

  • Where the price sits between its 52-week low and high.

  • Performance versus SPY compares the stock's returns to the S&P 500 index.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

News · shown, not counted

Global News
56

Technical score by timeframe

ChartScoreWeight
Hourly381
Daily213
Weekly272
Monthly422

Composite score, last 90 days

05010040Aug 22, 2026Nov 19, 2026Aug 22, 2026: 53Aug 23, 2026: 53Aug 24, 2026: 51Aug 25, 2026: 54Aug 26, 2026: 54Aug 27, 2026: 53Aug 28, 2026: 51Aug 29, 2026: 51Aug 30, 2026: 51Aug 31, 2026: 51Sep 1, 2026: 52Sep 2, 2026: 53Sep 3, 2026: 55Sep 4, 2026: 52Sep 5, 2026: 52Sep 6, 2026: 52Sep 7, 2026: 52Sep 8, 2026: 51Sep 9, 2026: 50Sep 10, 2026: 49Sep 11, 2026: 48Sep 12, 2026: 48Sep 13, 2026: 48Sep 14, 2026: 47Sep 15, 2026: 46Sep 16, 2026: 47Sep 17, 2026: 50Sep 18, 2026: 48Sep 19, 2026: 48Sep 20, 2026: 48Sep 21, 2026: 49Sep 22, 2026: 50Sep 23, 2026: 48Sep 24, 2026: 48Sep 25, 2026: 47Sep 26, 2026: 47Sep 27, 2026: 47Sep 28, 2026: 45Sep 29, 2026: 45Sep 30, 2026: 47Oct 1, 2026: 45Oct 2, 2026: 43Oct 3, 2026: 42Oct 4, 2026: 43Oct 5, 2026: 42Oct 6, 2026: 43Oct 7, 2026: 42Oct 8, 2026: 43Oct 9, 2026: 44Oct 10, 2026: 44Oct 11, 2026: 44Oct 12, 2026: 43Oct 13, 2026: 42Oct 14, 2026: 40Oct 15, 2026: 42Oct 16, 2026: 40Oct 17, 2026: 40Oct 18, 2026: 40Oct 19, 2026: 40Oct 20, 2026: 42Oct 21, 2026: 43Oct 22, 2026: 41Oct 23, 2026: 39Oct 24, 2026: 39Oct 25, 2026: 39Oct 26, 2026: 39Oct 27, 2026: 39Oct 28, 2026: 39Oct 29, 2026: 41Oct 30, 2026: 41Oct 31, 2026: 42Nov 1, 2026: 43Nov 2, 2026: 43Nov 3, 2026: 43Nov 4, 2026: 39Nov 5, 2026: 37Nov 6, 2026: 36Nov 7, 2026: 37Nov 8, 2026: 37Nov 10, 2026: 37Nov 11, 2026: 39Nov 12, 2026: 38Nov 13, 2026: 41Nov 14, 2026: 41Nov 15, 2026: 40Nov 16, 2026: 40Nov 17, 2026: 40Nov 18, 2026: 40Nov 19, 2026: 40
Show the daily numbers
DateComposite
Nov 19, 202640
Nov 18, 202640
Nov 17, 202640
Nov 16, 202640
Nov 15, 202640
Nov 14, 202641
Nov 13, 202641
Nov 12, 202638
Nov 11, 202639
Nov 10, 202637
Nov 8, 202637
Nov 7, 202637
Nov 6, 202636
Nov 5, 202637
Nov 4, 202639
Nov 3, 202643
Nov 2, 202643
Nov 1, 202643
Oct 31, 202642
Oct 30, 202641
Oct 29, 202641
Oct 28, 202639
Oct 27, 202639
Oct 26, 202639
Oct 25, 202639
Oct 24, 202639
Oct 23, 202639
Oct 22, 202641
Oct 21, 202643
Oct 20, 202642
Oct 19, 202640
Oct 18, 202640
Oct 17, 202640
Oct 16, 202640
Oct 15, 202642
Oct 14, 202640
Oct 13, 202642
Oct 12, 202643
Oct 11, 202644
Oct 10, 202644
Oct 9, 202644
Oct 8, 202643
Oct 7, 202642
Oct 6, 202643
Oct 5, 202642
Oct 4, 202643
Oct 3, 202642
Oct 2, 202643
Oct 1, 202645
Sep 30, 202647
Sep 29, 202645
Sep 28, 202645
Sep 27, 202647
Sep 26, 202647
Sep 25, 202647
Sep 24, 202648
Sep 23, 202648
Sep 22, 202650
Sep 21, 202649
Sep 20, 202648
Sep 19, 202648
Sep 18, 202648
Sep 17, 202650
Sep 16, 202647
Sep 15, 202646
Sep 14, 202647
Sep 13, 202648
Sep 12, 202648
Sep 11, 202648
Sep 10, 202649
Sep 9, 202650
Sep 8, 202651
Sep 7, 202652
Sep 6, 202652
Sep 5, 202652
Sep 4, 202652
Sep 3, 202655
Sep 2, 202653
Sep 1, 202652
Aug 31, 202651
Aug 30, 202651
Aug 29, 202651
Aug 28, 202651
Aug 27, 202653
Aug 26, 202654
Aug 25, 202654
Aug 24, 202651
Aug 23, 202653
Aug 22, 202653

Key facts

Market cap
$1.3B
Sector
Healthcare
Industry
Biotechnology
Beta
1.73
Risk grade (1–10)
10
Next earnings
Nov 4, 2026

Questions

What is NUVB's stock rating today?

NUVB scores 40/100 (Weak) as of Nov 19, 2026: technical 30, fundamental 42, and news sentiment 56, which is shown but not counted. Scores are recomputed every night.

What does Nuvation Bio do?

Nuvation Bio (NUVB) is a commercial-stage biopharmaceutical company that develops and sells targeted cancer therapies. Its marketed drug, IBTROZI, is a pill for adults with advanced non-small cell lung cancer driven by ROS1 gene fusions, and it gained the drug through its acquisition of AnHeart Therapeutics.

Is NUVB stock a buy?

The score is not a buy or sell recommendation. A 40 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the NUVB score calculated?

99 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

NUVB stock score

HTML

<a href="https://stocksscores.com/stocks/nuvb/"><img src="https://stocksscores.com/stocks/nuvb/badge.svg" alt="NUVB stock score" height="20"></a>

Markdown

[![NUVB stock score](https://stocksscores.com/stocks/nuvb/badge.svg)](https://stocksscores.com/stocks/nuvb/)